Bioproduction tools company BioLife Solutions Inc (NASDAQ:BLFS) said on Wednesday that its new SciSafe division has announced a two year contract for cold chain management and storage of COVID-19 vaccines.
The two year contract, valued at approximately USD2.7m, is awarded by a large pharmaceutical client.
In addition, the management expects SciSafe to contribute approximately USD9m in incremental revenue in 2021.
Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant state-of-the-art sample management facilities. Its clients have repeatedly chosen to store their most valued and irreplaceable biological samples.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses